Document:

Third Amendment to Services Agreement - Elan Drug Delivery, Inc.

 Exhibit 10.36 
 March 2, 2009 
 Via Overnight Mail and Email 
 Elan Drug Delivery, Inc. 
 3000 Horizon Drive 
 King of Prussia, PA 19406 

	Attn:	James L. Botkin, President and Chief Executive Officer 

 MAP
Pharmaceuticals, Inc. 
 2400 Bayshore Parkway, Suite 200 
 Mountain View, CA 94043 

	Attn:	Timothy S. Nelson, President and Chief Executive Officer 

  

	Re:	Third Amendment to Services Agreement 

 Dear Mr. Botkin and
Mr. Nelson: 
 Reference is made to that certain Services Agreement (such
agreement, as amended, the “Services Agreement”), dated 3rd February 2005, by and between Elan Drug Delivery, Inc.
(“EDDI”) and MAP Pharmaceuticals, Inc. (“MAP”), as amended by that certain First Amendment thereto (such amendment, the “First Amendment”), dated 18th December 2008, by and between EDDI and MAP and, with respect to which amendment, AstraZeneca AB is a party to the extent set forth in Section 7 thereof, and as further
amended by that Second Amendment thereto, dated 17 February 2009, by and between EDDI, MAP, and AstraZeneca AB. 
 Pursuant to Clause
10.5.1 of the Services Agreement, AstraZeneca AB and EDDI’s affiliate, Elan Pharma International Ltd. (“EPIL”), are required to negotiate the terms and conditions of the Manufacturing Agreement (as such term is used in the
Services Agreement) in good faith and with such diligence as is required to execute and deliver such agreement within [***] after the First Amendment Effective Date (as defined in the First Amendment) or such other period as AstraZeneca AB and EPIL
may agree in writing. Pursuant to Clause 10.5A of the Services Agreement, AstraZeneca AB and EPIL are required to [***]. 
 AstraZeneca AB
and EPIL are in the process of negotiating the terms and conditions of the manufacturing agreement and [***], and desire to amend the Services Agreement to [***]. 
 EDDI, MAP, and AstraZeneca AB hereby agree as follows: 
 1. In the first sentence of Clause 10.5.1 of the
Services Agreement, the phrase “within [***] after the First Amendment Effective Date, or such other period as the Negotiating Parties may agree in writing” is hereby amended to read as follows: “on or before [***], or such other date
as the Negotiating Parties may agree in writing.” 
  
 [*] = Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 2. The final sentence in Clause 10.5A of the Services Agreement is hereby amended to read as follows:

 “EPIL and the Sublicense Counter Party shall [***] on or before [***], or such other date as the Negotiating Parties may agree in
writing.” 
 3. This letter agreement and the rights and obligations of EDDI, MAP, and AstraZeneca AB hereunder shall be governed by and
construed under the laws of the State of New York, without regard to its choice of laws provisions. This letter agreement and the Services Agreement, as amended, constitute the entire agreement between EDDI, MAP, and AstraZeneca AB with respect to
the subject matter hereof and all prior agreements with respect thereto are superseded hereby. No amendment or modification hereto shall be binding unless in writing and duly executed by the authorized representatives of EDDI, MAP, and AstraZeneca
AB. This letter agreement may be executed in one or more counterpart copies, each of which shall be deemed an original and all of which shall together be deemed to constitute one agreement. 
 [Signature page follows] 
  
 [*] = Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Please sign and date this letter agreement in the space provided below to confirm the mutual agreements
set forth herein. 
  

			
	Very truly yours,
	
	ASTRAZENECA AB (publ)
		
	By:	 	[***]
	Name:	 	[***]
	Title:	 	Authorised Signatory
		
	Date:	 	March 2, 2009

 Accepted and agreed as of the date written below: 
  

			
	ELAN DRUG DELIVERY, INC.
		
	By:	 	/s/ James L. Botkin
	Name:	 	James L. Botkin
	Title:	 	President & CEO
		
	Date:	 	March 2, 2009

 Accepted and agreed as of the date written below: 
  

			
	MAP PHARMACEUTICALS, INC.
		
	By:	 	/s/ Timothy S. Nelson
	Name:	 	Timothy S. Nelson
	Title:	 	President & CEO
		
	Date:	 	March 2, 2009

  
 [*] = Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Offer Letter dated July 5, 2007 - Charlene A. Friedman

 Exhibit 10.37 

			
	

	  	  
 2400 Bayshore Parkway
 Mountain View, CA 94043
 650.386.3100 Tel
 650.386.3101 Fax
 www.mappharma.com

  

 July 5, 2007 
  
 Dear Charlene: 
 We are pleased to extend to you this offer of employment
with MAP Pharmaceuticals, Inc. under the following terms and conditions. 
 Your title will be Vice President, General Counsel and Corporate Secretary
reporting directly to me. Your starting bi-weekly compensation will be $9432.00, annualized to $245,000. 
 You will be eligible for MAP’s bonus
program, which is currently an MBO based program with a target goal set at 25%. This program is subject to annual review by the board 
 Although the
issuance of stock options is in the discretion of the Compensation Committee of MAP’s Board of Directors, we anticipate that the Compensation Committee will approve the issuance of an option of 150,000 shares of MAP common stock options to you
in connection with the commencement of your full time employment. 
 You will be eligible for the Executive Standard Severance Package, with the exception
that if, prior to the earlier of November 30, 2007 or Map’s Initial Public Offering, the Company is acquired, 25% of your stock grant will vest rather than 100%. 
 As a MAP employee, you will also be eligible for full company benefits, which include Health, Dental, Life, Vision, Vacation and Holidays 
 This offer is contingent upon your ability to show satisfactory proof of identity and authorization to work in the United States. Please bring the appropriate verification documents (see enclosed document), on your
first day of employment. This offer is also contingent upon the successful completion of our employment background check and drug test. You will be provided with information and instructions on the completion of these items and cannot begin your
employment until cleared results have been received. 
 On your first day of employment, you will be required to execute the company’s Confidentiality
and Assignment of Inventions Agreement, providing for protection of the company’s proprietary information and trade secrets. We ask that you make every effort to protect the confidential and proprietary information of your current employer.

			
	

	  	  
 2400 Bayshore Parkway
 Mountain View, CA 94043
 650.386.3100 Tel
 650.386.3101 Fax
 www.mappharma.com

  

 Charlene Friedman – Page 2 
 As part of employment at MAP Pharmaceuticals, Inc., you will be required to attend Safety Training. Additional information will be given to you upon joining the organization. 
 Charlene, we look forward to having you join the MAP Pharmaceuticals, Inc. team! We believe you will find that MAP Pharmaceuticals, Inc. provides a unique, rewarding
work experience. 
 Please contact me if you have any questions regarding this offer of employment. You may accept this offer by signing below and returning
the signed copy, the second copy is for your records. 
  
 Sincerely, 
 /s/ Tim Nelson 
 Tim Nelson 
 President and Chief Executive Officer 
 I understand that this letter is not
a contract, expressed or implied, guaranteeing employment, or employment for any duration. If you choose to accept this offer, you will be an “at will” employee, and your employment with MAP will be voluntarily entered into and will be for
no specified period. As a result, you will be free to resign at any time, for any reason or for no reason, as you deem appropriate. MAP will have a similar right, and may conclude our employment relationship with you at any time, with or without
cause. Additionally, we may withdraw this offer at any time, with or without notice to you. The provisions stated in this offer of employment supersede all prior discussions and negotiations, and no other writing published by MAP Pharmaceuticals,
Inc. is intended to modify the presumptions of at-will employment status. 
 This offer will expire on July 9, 2007 and it is expected that you will be
available to start work on or around July 24, 2007. 
  
  

									
	 /s/ Charlene Friedman
 Charlene Friedman
	 		 	  
 Start
DateAmendment No. 1 to the Rewards Network Inc. 2006 Long-Term Incentive Plan

 Exhibit 10.10 
 AMENDMENT NUMBER ONE 
 TO THE 
 REWARDS NETWORK INC. 
 2006 LONG-TERM INCENTIVE PLAN 
 WHEREAS, Rewards Network Inc., a Delaware corporation (the “Company”), has heretofore adopted and maintains the Rewards Network Inc.
2006 Long-Term Incentive Plan (the “Plan”); 
 WHEREAS, the Board of Directors of the Company (the “Board”) has
retained the power to amend the Plan; and 
 WHEREAS, the Board has authorized the amendment of the Plan to comply with final
regulations issued under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). 
 NOW THEREFORE,
pursuant to the power of amendment contained in Section 8(e) of the Plan, the Plan is hereby amended, effective as of January 1, 2009, as follows: 
 1. Section 2(h) of the Plan is hereby amended by adding “in accordance with Section 409A of the Code” immediately prior to the proviso set forth therein. 
 2. Section 6(c)(i) of the Plan is hereby amended by adding the phrase “and permitted under Section 409A of the Code” immediately
after the phrase “except as provided in Section 7(a),” where it appears therein. 
 3. Section 6(e)(i) of the Plan is
hereby amended by adding “in accordance with Section 409A of the Code” at the end of the first sentence thereof. 

 IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized
agent on this 31st day of December, 2008. 
  

			
	REWARDS NETWORK INC.
		
	By:	 	 /s/ Ronald L. Blake

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]